title: Repositioning 'old' drugs to treat rare diseases: arguing from the mechanism of action.
authors.affiliation: ILD Center of Excellence, St. Antonius Hospital, Nieuwegein &. m.drent@hetnet.nl.
authors.forename: Marjolein
authors.initials: M
authors.lastname: Drent
authors.forename: Aalt
authors.initials: A
authors.lastname: Bast
authors.forename: Hans-Peter
authors.initials: HP
authors.lastname: Bootsma
authors.forename: Vera
authors.initials: V
authors.lastname: Deneer
mesh_terms: D000284:Administration, Oral; D000631:Aminopyridines / Q000008:administration & dosage*; D001549:Benzamides / Q000008:administration & dosage*; D003521:Cyclopropanes / Q000008:administration & dosage; D058492:Drug Repositioning; D019317:Evidence-Based Medicine; D005260:Female; D006646:Histiocytosis, Langerhans-Cell / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008875:Middle Aged; D009965:Orphan Drug Production; D058988:Phosphodiesterase 4 Inhibitors / Q000008:administration & dosage*; D035583:Rare Diseases / Q000188:drug therapy*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000631:Aminopyridines; D001549:Benzamides; D003521:Cyclopropanes; D058988:Phosphodiesterase 4 Inhibitors; C424423:Roflumilast
keywords: histiocytosis-X, orphan drugs, pharmacological treatment, rare disease